Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis

被引:127
作者
Beccaria, M
Luisetti, M
Rodi, G
Corsico, A
Zoia, MC
Colato, S
Pochetti, P
Braschi, A
Pozzi, E
Cerveri, I
机构
[1] Univ Pavia, Policlin San Matteo, Div Resp Dis, IRCCS, I-27100 Pavia, Italy
[2] Univ Pavia, Policlin San Matteo, Anaesthesiol & Intens Care Unit, IRCCS, I-27100 Pavia, Italy
关键词
bronchoalveolar lavage; follow-up studies; pulmonary alveolar proteinosis; respiratory function tests;
D O I
10.1183/09031936.04.00102704
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Whole lung lavage (WLL) is still the gold-standard therapy for pulmonary alveolar proteinosis (PAP). The few studies on the duration of the effect of WLL, belonging to a rather remote period, show significant but transient benefits. In 21 patients with idiopathic PAP, the duration of any benefit and, in 16 of them, the time course of lung function improvement (at baseline, 1 week, 6 months, I yr and then every 2 yrs after WLL) were evaluated. The present WLL technique takes longer, is invasively monitored and partially modified with respect to past techniques. More than 70%,, of patients remained free from recurrent PAP at 7 yrs. The bulk of the improvement in spirometric results was almost completely gained in the immediate post-WLL period due to the efficient clearance of the alveoli. At a median of 5 yrs, recovery of diffusing capacity of the lung for carbon monoxide was incomplete (75+/-19 % of the predicted value) and there were residual gas exchange abnormalities (alveolar to arterial oxygen tension difference 3.6+/-1.5 kPa (27+/-11 mmHg)) and exercise limitation, probably explained by engorgement of lymphatic vessels. In conclusion, whole lung lavage for idiopathic pulmonary alveolar proteinosis is currently a safe procedure in an experienced setting, and provides long-lasting benefits in the majority of patients.
引用
收藏
页码:526 / 531
页数:6
相关论文
共 29 条
[11]  
KAO D, 1975, AM REV RESPIR DIS, V111, P361
[12]   PULMONARY ALVEOLAR PROTEINOSIS - PROSPECTIVE CLINICAL-EXPERIENCE IN 23 PATIENTS FOR 15 YEARS [J].
KARIMAN, K ;
KYLSTRA, JA ;
SPOCK, A .
LUNG, 1984, 162 (04) :223-231
[13]   Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis [J].
Kavuru, MS ;
Sullivan, EJ ;
Piccin, R ;
Thomassen, MJ ;
Stoller, JK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1143-1148
[14]   Therapeutic whole lung lavage - A stop-gap therapy for alveolar proteinosis [J].
Kavuru, MS ;
Popovich, M .
CHEST, 2002, 122 (04) :1123-1124
[15]   Pulmonary alveolar proteinosis - High-resolution CT, chest radiographic, and functional correlations [J].
Lee, KN ;
Levin, DL ;
Webb, WR ;
Chen, DR ;
Storto, ML ;
Golden, JA .
CHEST, 1997, 111 (04) :989-995
[16]   Pulmonary alveolar proteinosis: Recent advances [J].
Mazzone, PJ ;
Thomassen, MJ ;
Kavuru, MS .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 23 (02) :115-126
[17]   PULMONARY ALVEOLAR PHOSPHOLIPOPROTEINOSIS - EXPERIENCE WITH 34 CASES AND A REVIEW [J].
PRAKASH, UBS ;
BARHAM, SS ;
CARPENTER, HA ;
DINES, DE ;
MARSH, HM .
MAYO CLINIC PROCEEDINGS, 1987, 62 (06) :499-518
[18]   LUNG-VOLUMES AND FORCED VENTILATORY FLOWS - REPORT WORKING PARTY STANDARDIZATION OF LUNG-FUNCTION TESTS EUROPEAN-COMMUNITY FOR STEEL AND COAL - OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY [J].
QUANJER, PH ;
TAMMELING, GJ ;
COTES, JE ;
PEDERSEN, OF ;
PESLIN, R ;
YERNAULT, JC .
EUROPEAN RESPIRATORY JOURNAL, 1993, 6 :5-40
[19]  
RAMIREZ RJ, 1966, DIS CHEST, V50, P544
[20]  
RODI G, 1995, MONALDI ARCH CHEST D, V1, P64